Public Announcement
FOR IMMEDIATE RELEASE
Puresyn and Evolyra Announce Strategic Collaboration to Advance Gene Therapy for Limb-Girdle Muscular Dystrophies
Malvern, PA and Richmond, VA – Puresyn, a specialized provider of plasmid DNA development and manufacturing services, today announced a strategic collaboration with Evolyra Therapeutics, a gene therapy company focused on creating a faster path to a cure for inherited muscle diseases.
This collaboration is designed to accelerate the development of innovative therapeutic approaches by combining Evolyra’s novel Limb-Girdle Muscular Dystrophy treatment with Puresyn’s capabilities in high‑quality plasmid DNA production.
Under the terms of the collaboration, Puresyn will provide phase‑appropriate plasmid DNA services to support Evolyra’s research and development programs, including preclinical and clinical-stage initiatives. The parties will work closely to optimize plasmid scale-up and manufacturing workflows that are suitable for regulatory submissions and meet an accelerated timeline while being cost-conscious.
“We’re deeply inspired by the rare disease community—its passion and commitment bring a contagious energy that motivates our entire team. Our collaboration with Ellie at Evolyra on their Limb Girdle Muscular Dystrophies clinical trials exemplifies this spirit and reinforces our dedication to supporting these efforts in every way possible,” said Michael Moxley, Director of Business and Process Development at Puresyn.
“Puresyn has been an incredible partner to Evolyra; their knowledge, communication, and high-quality plasmids help us ensure we have the best starting materials for our gene therapy development,” said Ellie Carrell, Evolyra’s Chief Science Officer.
The collaboration underscores a shared commitment to addressing the specific needs of rare diseases. By leveraging complementary strengths, the parties intend to streamline plasmid manufacturing activities, reduce operational risk, and create a framework that supports current and future clinical requirements.
About Puresyn
Puresyn is a contract development and manufacturing organization specializing in plasmid DNA services, offering research-grade, INDReady®, and cGMP plasmid production supported by established quality systems and scalable manufacturing infrastructure. Puresyn supports biopharmaceutical and cell and gene therapy companies from early discovery through commercial development with a focus on reliability, technical excellence, and responsive collaboration.
About Evolyra Therapeutics
Evolyra Therapeutics, headquartered in Richmond, Virginia, is dedicated to developing transformative gene therapies for rare neuromuscular diseases, with an initial focus on the Limb-Girdle Muscular Dystrophy (LGMD). The company is advancing a next-generation gene therapy platform built on muscle targeting adeno-associated virus (AAV) vectors designed to deliver full-length functional genes directly to skeletal muscle while minimizing off-target effects such as liver toxicity. This differentiated approach aims to overcome safety and efficacy limitations observed in earlier gene therapy programs. Evolyra is initially targeting LGMD subtypes 2C and 2D—progressive, currently untreatable conditions that lead to severe muscle degeneration and reduced quality of life—but envisions a scalable and modular platform strategy, enabling the development of full gene replacement therapies across more than 20 LGMD subtypes and potentially other genetic diseases. Evolyra integrates clinical expertise, translational research, and patient-driven data through collaborations with academic leaders and global patient consortia to accelerate development and improve trial readiness. Founded by physicians, scientists and biotech leaders, Evolyra Therapeutics emphasizes a patient-centric model focused on safety, precision, and speed. For more information, please visit https://evolyratherapeutics.com.
Media Contact:
Evolyra Therapeutics:
Nicholas Johnson, MD
CEO
Nicholas.johnson@evolyratherapeutics.com
Puresyn:
Leslie M. Flynn
VP & General Manager
leslie@puresyn.com